Yifan Pharmaceutical Co., Ltd. (SHE:002019)
China · Delayed Price · Currency is CNY 11.98
+0.15 (1.27%)
Feb 3, 2026, 3:04 PM CST
Yifan Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 5,204 | 5,140 | 4,044 | 3,819 | 4,379 | 5,369 |
Other Revenue | 20.29 | 20.29 | 23.61 | 17.51 | 30.45 | 31.39 |
| 5,224 | 5,160 | 4,068 | 3,837 | 4,409 | 5,400 | |
Revenue Growth (YoY) | 4.57% | 26.84% | 6.03% | -12.98% | -18.36% | 4.12% |
Cost of Revenue | 2,835 | 2,808 | 2,159 | 1,983 | 2,594 | 2,899 |
Gross Profit | 2,390 | 2,352 | 1,909 | 1,853 | 1,815 | 2,501 |
Selling, General & Admin | 1,583 | 1,629 | 1,503 | 1,435 | 1,297 | 1,111 |
Research & Development | 301.39 | 291.97 | 312.38 | 190.2 | 196.64 | 325.34 |
Other Operating Expenses | 68.26 | 43.52 | 32.37 | 27.05 | 37.24 | 42.11 |
Operating Expenses | 1,992 | 2,026 | 1,908 | 1,682 | 1,552 | 1,487 |
Operating Income | 398.13 | 326.09 | 1.09 | 171.35 | 262.68 | 1,014 |
Interest Expense | -58.81 | -69.1 | -75.55 | -85.85 | -74.59 | -71.07 |
Interest & Investment Income | 8.97 | 8.12 | 13.13 | 21.39 | 25.3 | 33.21 |
Currency Exchange Gain (Loss) | -2.94 | -2.94 | 14.5 | 50.19 | -17.77 | -18.06 |
Other Non Operating Income (Expenses) | -4.75 | -7.66 | -14.84 | -12.38 | -8.03 | -3.06 |
EBT Excluding Unusual Items | 340.6 | 254.51 | -61.68 | 144.69 | 187.59 | 954.93 |
Impairment of Goodwill | - | - | - | - | -11.9 | - |
Gain (Loss) on Sale of Investments | -30.21 | -14.16 | -15.06 | -17.63 | -4.49 | -0.01 |
Gain (Loss) on Sale of Assets | 5.53 | 30.15 | 2.57 | -0.56 | 14.83 | -0.04 |
Asset Writedown | -6.79 | -11.48 | -852.58 | -102.13 | -26.34 | -6.6 |
Other Unusual Items | 129.28 | 129.65 | 57.71 | 132.37 | 51.1 | 132.44 |
Pretax Income | 438.41 | 388.66 | -869.03 | 156.74 | 210.79 | 1,081 |
Income Tax Expense | 62.3 | 65.04 | 16.62 | 29.65 | -31.42 | 149.32 |
Earnings From Continuing Operations | 376.11 | 323.62 | -885.65 | 127.09 | 242.21 | 931.39 |
Minority Interest in Earnings | 31.26 | 62.35 | 334.58 | 64.13 | 36.18 | 37 |
Net Income | 407.37 | 385.97 | -551.07 | 191.22 | 278.4 | 968.39 |
Net Income to Common | 407.37 | 385.97 | -551.07 | 191.22 | 278.4 | 968.39 |
Net Income Growth | - | - | - | -31.31% | -71.25% | 7.19% |
Shares Outstanding (Basic) | 1,199 | 1,206 | 1,225 | 1,195 | 1,210 | 1,210 |
Shares Outstanding (Diluted) | 1,199 | 1,206 | 1,225 | 1,275 | 1,210 | 1,226 |
Shares Change (YoY) | -1.94% | -1.51% | -3.94% | 5.32% | -1.26% | 0.40% |
EPS (Basic) | 0.34 | 0.32 | -0.45 | 0.16 | 0.23 | 0.80 |
EPS (Diluted) | 0.34 | 0.32 | -0.45 | 0.15 | 0.23 | 0.79 |
EPS Growth | - | - | - | -34.78% | -70.89% | 6.76% |
Free Cash Flow | -62.48 | 12.57 | -155.5 | -70.21 | -270.51 | 392.8 |
Free Cash Flow Per Share | -0.05 | 0.01 | -0.13 | -0.06 | -0.22 | 0.32 |
Dividend Per Share | 0.100 | 0.200 | - | - | - | 0.050 |
Dividend Growth | - | - | - | - | - | -50.00% |
Gross Margin | 45.74% | 45.59% | 46.93% | 48.30% | 41.16% | 46.31% |
Operating Margin | 7.62% | 6.32% | 0.03% | 4.47% | 5.96% | 18.77% |
Profit Margin | 7.80% | 7.48% | -13.55% | 4.98% | 6.31% | 17.93% |
Free Cash Flow Margin | -1.20% | 0.24% | -3.82% | -1.83% | -6.13% | 7.27% |
EBITDA | 762.76 | 642.69 | 253.66 | 379.13 | 453.82 | 1,191 |
EBITDA Margin | 14.60% | 12.46% | 6.24% | 9.88% | 10.29% | 22.05% |
D&A For EBITDA | 364.62 | 316.6 | 252.57 | 207.78 | 191.14 | 177.01 |
EBIT | 398.13 | 326.09 | 1.09 | 171.35 | 262.68 | 1,014 |
EBIT Margin | 7.62% | 6.32% | 0.03% | 4.47% | 5.96% | 18.77% |
Effective Tax Rate | 14.21% | 16.73% | - | 18.92% | - | 13.82% |
Revenue as Reported | 5,224 | 5,160 | 4,068 | 3,837 | 4,409 | 5,400 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.